Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells

Jordi Codony-Servat, Joan Albanell, Juan Carlos Lopez-Talavera, Joaquín Arribas, José Baselga

Research output: Contribution to journalArticleResearchpeer-review

217 Citations (Scopus)

Abstract

HER2/neu, a M(r) 185,000 tyrosine kinase receptor that is overexpressed in breast cancer, undergoes proteolytic cleavage of its extracellular domain (ECD). In contrast with other membrane-bound proteins, including growth factor receptors, that are cleaved by a common machinery system, we show that HER2 cleavage is a slow process and is not activated by protein kinase C. Pervanadate, a general inhibitor of protein-tyrosine phosphatases, induces a rapid and potent shedding of HER2 ECD. The shedding of HER2 ECD is inhibited by the broad-spectrum metalloprotease inhibitors EDTA, TAPI-2, and batimastat. The tissue inhibitor of metalloproteases-1; an inhibitor of matrix metalloproteases that does not inhibit cleavage by the general protein kinase C-dependent shedding machinery, also inhibited HER2 ECD shedding, whereas tissue inhibitor of metalloproteases-2 did not. These data suggest that HER2 cleavage is a process regulated by an as-yet-unidentified distinct protease.
Original languageEnglish
Pages (from-to)1196-1201
JournalCancer Research
Volume59
Issue number6
Publication statusPublished - 15 Mar 1999

Fingerprint Dive into the research topics of 'Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells'. Together they form a unique fingerprint.

  • Cite this

    Codony-Servat, J., Albanell, J., Lopez-Talavera, J. C., Arribas, J., & Baselga, J. (1999). Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Research, 59(6), 1196-1201.